10X Genomics & Harvard v. Bruker Spatial Biology: Six-Patent Spatial Biology Dispute Dismissed With Prejudice
10X Genomics and Harvard jointly sued Bruker Spatial Biology in Delaware over six spatial transcriptomics patents covering the CosMx SMI platform. After 1,170 days of litigation, all claims and counterclaims were dismissed with prejudice by stipulation — each party bearing its own fees and costs.
A Six-Patent Spatial Biology Standoff Ends in Bilateral Walkaway
Filed on 28 February 2022 in the District of Delaware, this action saw 10X Genomics, Inc. and the President and Fellows of Harvard College assert six US patents — US11293051B2, US11542554B2, US11293054B2, US11021737B2, US11293052B2, and US10227639B2 — against Bruker Spatial Biology, Inc. (formerly NanoString Technologies). The asserted patents cover spatial transcriptomics methods and compositions, and the accused products centre on NanoString’s CosMx Spatial Molecular Imager (SMI) platform, including instruments, software, reagents, and consumables.
The case closed on 13 May 2025 via a stipulated dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims and counterclaims were dismissed, with each party bearing its own costs and attorneys’ fees. The ‘with prejudice’ designation means plaintiffs are permanently barred from reasserting the same claims against Bruker on the same patents in a new action — a significant procedural finality.
At 1,170 days, the case ran for over three years before resolving without a merits judgment, suggesting the parties likely reached a negotiated resolution — possibly a licensing arrangement or commercial agreement — prior to the formal stipulation. The simultaneous dismissal of all counterclaims and the mutual cost-bearing provision are consistent with a negotiated settlement, though the public record does not confirm specific terms. What drove the timing — whether triggered by Bruker’s 2023 acquisition of NanoString assets out of bankruptcy, parallel IPR proceedings, or commercial factors — remains undisclosed.
Filing to Dismissed with Prejudice in 1170 days
1,170 days — well above the ~700-day median for patent cases in Delaware District Court
Dismissed with prejudice: what the stipulated walkaway means for both sides
Rule 41(a)(1)(A)(ii) dismissal with prejudice explained
A stipulated dismissal under FRCP 41(a)(1)(A)(ii) requires agreement from all parties and is entered by the court as a final judgment. The ‘with prejudice’ designation carries res judicata effect — 10X Genomics and Harvard cannot refile these specific claims against Bruker on the same six patents. This is the strongest form of voluntary dismissal and typically signals a comprehensive resolution between the parties.
Permanent bar on refilingPlaintiffs accept finality — no infringement finding on record
By agreeing to dismissal with prejudice, 10X Genomics and Harvard forgo any court-declared infringement ruling and any damages award against Bruker. The patents remain valid and enforceable — they were neither invalidated nor adjudicated — but the dismissal prevents future assertion of these specific claims against Bruker. Plaintiffs retain the right to assert these patents against other parties in the spatial transcriptomics market.
Patents intact; Bruker claim extinguishedBruker escapes infringement finding but litigation risk cost is real
Bruker Spatial Biology avoids any court-ordered damages or injunction on the CosMx SMI platform. The with-prejudice dismissal provides certainty: 10X Genomics and Harvard cannot revive this specific action. However, no invalidity ruling was obtained — the six asserted patents stand unchallenged in this forum. Bruker’s own cost-bearing obligation means three years of legal spend produced no declaratory judgment of non-infringement or invalidity.
No injunction; no invalidity rulingSpatial transcriptomics IP landscape remains unsettled
The absence of a merits ruling leaves the validity and scope of 10X Genomics’ and Harvard’s spatial transcriptomics patent portfolio unresolved for the broader market. Competitors in the CosMx SMI and spatial biology space cannot rely on this case to assess freedom to operate. The resolution — likely driven partly by Bruker’s acquisition of NanoString assets from bankruptcy — may signal a commercial détente, but the underlying patents remain live enforcement tools against other market entrants.
Portfolio risk persists for third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | 10X Genomics, Inc. | Company | Spatial genomics technology company and Harvard — co-holders of 6 spatial transcriptomics patentsSearch in Eureka ↗ |
| Co-Plaintiff | President and Fellows of Harvard College | Individual | Search in Eureka ↗ |
| Defendant | Bruker Spatial Biology, Inc. | Company | Bruker Spatial Biology, Inc. — provider of the CosMx SMI spatial molecular imaging platformSearch in Eureka ↗ |
| Plaintiff counsel | Aaron Nathan | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Ewing | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Azra M. Hadzimehmedovic | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Cameron Paul Clark | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gabriela Monasterio | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Grace Gretes | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jason James Rawnsley | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Karen Jacobs | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kiley White | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Li Shen | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew D. Powers | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Paul T. Ehrlich | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert L. Gerrity | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ronald J. Pabis | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Samantha A. Jameson | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stefani C. Smith | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Nelson | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Richards, Layton & Finger, PA | Law Firm | Representing 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Adam Adler | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Anne Corbett | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | August M. Melcher | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian E. Farnan | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Christine E. Lehman | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher M. Pepe | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Courtland L. Reichman | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | David King | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Derek C. Walter | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Edward R. Reines | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric S. Hochstadt | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | John E. Scribner | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Karnik F. Hajjar | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Kristin Sanford | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael J. Farnan | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Natalie C. Kennedy | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Sarah O. Jorgensen | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Savannah H. Carnes | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Spencer Talbot | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Yi Zhang | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant law firm | Farnan LLP | Law Firm | Representing Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant law firm | Orrick, Herrington & Sutcliffe LLP | Law Firm | Representing Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Matthew F. Kennelly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text is a joint stipulation under FRCP 41(a)(1)(A)(ii), reflecting a bilateral agreement to end all claims and counterclaims with prejudice. The explicit ‘each party shall bear its own costs’ provision removes any fee-shifting signal, suggesting neither side was positioned to claim exceptional case status under 35 U.S.C. § 285. Critically, no merits adjudication occurred — no claim construction, infringement finding, or invalidity ruling is embedded in this dismissal. The with-prejudice designation provides Bruker with finality on these specific claims, while leaving 10X Genomics’ and Harvard’s patent portfolio fully intact for enforcement against the broader spatial transcriptomics market.
US11293051B2 — Spatial Transcriptomics: In Situ Gene Expression Detection
The six asserted patents — US11293051B2, US11542554B2, US11293054B2, US11021737B2, US11293052B2, and US10227639B2 — collectively cover foundational spatial transcriptomics methods and compositions, including in situ detection of nucleic acids, spatial barcoding, and multiplexed gene expression analysis in intact tissue. Several of these patents trace to application filings in the 2014–2021 timeframe, reflecting a portfolio built around core innovations in spatial molecular imaging. The patents are jointly held by 10X Genomics and Harvard, the latter through its Wyss Institute and related research programmes.
Spatial transcriptomics has emerged as one of the fastest-growing segments in life science tools, with the CosMx SMI platform — the accused product — positioned as a direct competitor to 10X Genomics’ Visium and Xenium platforms. A portfolio of six patents covering in situ detection and spatial barcoding methods gives 10X Genomics and Harvard broad blocking potential across competing instruments, reagents, and software in this space. The absence of an invalidity ruling from this case means the portfolio carries full presumption of validity, making it a significant barrier to market entry for developers of competing spatial molecular imaging technologies.
Should you run an FTO against US11293051B2 and the 10X/Harvard spatial portfolio?
Any company developing instruments, reagents, software, or consumables for in situ spatial transcriptomics — particularly platforms using multiplexed imaging or spatial barcoding in tissue — should conduct a freedom-to-operate assessment against this six-patent portfolio. The CosMx SMI platform was accused in this action, signalling that 10X Genomics and Harvard are prepared to enforce these patents aggressively against commercial spatial biology platforms. The with-prejudice dismissal does not limit enforcement against third parties.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim scope across all six patents against their own spatial transcriptomics workflows. Eureka can identify which specific method steps — probe design, signal detection, spatial barcoding algorithms — fall within or outside the asserted claims, flag relevant prior art that could support design-arounds, and surface any pending continuation applications in the 10X/Harvard portfolio that may expand claim coverage. Run a structured FTO before committing to product development timelines in this space.
Run a freedom-to-operate analysis on US11293051B2 to assess your product’s exposure
Run FTO in Eureka →Related Spatial Transcriptomics & Genomics Patent Disputes in Delaware
Cases involving spatial transcriptomics and genomics platform patents litigated in Delaware District Court, including related 10X Genomics enforcement actions.
What this case signals for the spatial transcriptomics IP landscape
A three-year dispute over foundational spatial biology patents ends without a merits ruling — leaving the enforcement map unresolved.
Six core spatial transcriptomics patents remain enforceable after dismissal
None of the six asserted patents — including US11293051B2 and US10227639B2 — were invalidated or found unenforceable. The stipulated dismissal with prejudice resolves only the Bruker dispute. Companies building spatial molecular imaging products should treat this portfolio as an active enforcement risk and conduct FTO analysis before commercialising competing platforms.
Bankruptcy-driven asset acquisition can reshape active patent litigation
Bruker’s acquisition of NanoString assets during its 2023 bankruptcy proceedings likely complicated the litigation dynamics, potentially shifting settlement leverage. IP teams monitoring competitors in the spatial biology sector should track corporate restructuring events as litigation inflection points — a change in corporate ownership can rapidly alter enforcement calculus and settlement posture.
10X v Bruker — key questions answered
10X Genomics and Harvard asserted six US patents: US11293051B2, US11542554B2, US11293054B2, US11021737B2, US11293052B2, and US10227639B2. The patents cover spatial transcriptomics methods including in situ nucleic acid detection, spatial barcoding, and multiplexed gene expression analysis. The accused products centred on NanoString’s CosMx Spatial Molecular Imager platform.
The case was dismissed via a joint stipulation under FRCP 41(a)(1)(A)(ii) with each party bearing its own costs, consistent with a negotiated resolution. The public record does not disclose specific settlement terms. Bruker’s 2023 acquisition of NanoString assets out of bankruptcy proceedings likely influenced the litigation dynamics and may have been a factor in the timing of the resolution.
No. A dismissal with prejudice under Rule 41(a)(1)(A)(ii) carries no merits adjudication. The six asserted patents were not declared invalid or unenforceable in this proceeding. They retain their full presumption of validity and remain enforceable against third parties. Only the specific claims against Bruker are permanently extinguished by the with-prejudice designation.
NanoString’s CosMx Spatial Molecular Imager is a commercial platform for in situ spatial transcriptomics, enabling multiplexed detection of RNA and protein targets in intact tissue samples. It competes directly with 10X Genomics’ Xenium platform. 10X Genomics and Harvard alleged that CosMx instruments, software, reagents, and consumables infringed their portfolio of spatial transcriptomics patents covering the underlying detection and barcoding methods.
No. The dismissal was entered with prejudice, which under res judicata principles bars 10X Genomics and Harvard from reasserting the same claims against Bruker Spatial Biology on the same six patents. However, 10X Genomics retains full rights to enforce these patents against other parties in the spatial transcriptomics market, and no limitation on assertion against third-party competitors was established by this dismissal.
PatSnap Eureka searches patents and litigation data to answer instantly.